Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

BeOne Medicines (ONC.O)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (US$)	Price Target (US$)	Rating
2022-03-30	206.00	301.40	Buy
2022-05-06	147.29	282.50	Buy
2022-07-15	177.15	259.60	Buy
2022-08-05	194.47	241.80	Buy
2022-10-13	151.89	220.30	Buy
2022-11-10	188.80	239.20	Buy
2023-02-28	224.63	318.20	Buy
2023-09-19	208.86	310.80	Buy
2023-11-10	199.11	311.50	Buy
2024-02-28	178.48	285.70	Buy
2024-05-08	164.44	262.30	Buy
2024-08-07	176.73	281.60	Buy
2024-11-12	193.64	289.70	Buy
2025-02-27	278.38	330.00	Buy
2025-05-07	232.25	326.00	Buy

Disclosures

UBS Securities LLC makes a market in the securities and/or ADRs of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.